Polycystic ovary syndrome (PCOS), a condition affecting more than 170 million people worldwide, has officially been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) following a landmark global consensus study published in The Lancet.
The new name recognizes that the condition is not a primarily gynecological disorder, but is instead a complex, multisystem condition involving endocrine, metabolic, reproductive, dermatological and psychological health. Additionally, the re-categorizing will include updates to clinical guidelines, medical education and international disease classification systems, ensuring the new terminology is adopted consistently worldwide.
For decades, the term “polycystic ovary syndrome” has been widely recognized as inaccurate and limiting. Despite its name, many patients do not have ovarian cysts, which has obscured the condition’s broader health implications.
This mischaracterization has had tangible consequences: delayed diagnoses, fragmented care, stigma and missed opportunities for early intervention in metabolic and cardiovascular risks.
The name change is far more than cosmetic. It is expected to reshape how the condition is diagnosed, treated and researched globally.
By moving beyond a narrow reproductive framing, the “PMOS” name:
- Reflects the condition’s hormonal (polyendocrine) complexity
- Acknowledges its strong metabolic and cardiometabolic affects
- Continues to emphasize the role of ovaries without overemphasizing reproductive aspects
- Promotes earlier and more accurate diagnosis
- Supports more holistic, patient-centered care
- Reduces stigma associated with fertility-focused terminology
- Expands research into metabolic and systemic impacts
Data from University of Colorado Anschutz